Latest Conference Articles

July 19th 2022, 4:00pm

Pan Pacific Lymphoma Conference

Neha Mehta-Shah, MD, MSCI, discusses frontline therapies in peripheral T-cell lymphoma, highlighting the current treatment landscape and the need to explore more treatment options in clinical trials.

July 19th 2022, 1:10pm

Pan Pacific Lymphoma Conference

Avyakta Kallam, MBBS, discusses the benefits and shortcomings of the current standard of care in central nervous system lymphoma and expressed the importance of studying frontline targeted agents in this population.

July 16th 2022, 5:55pm

International Congress on the Future of Breast Cancer East

Neratinib-based combinations, antibody-drug conjugates, and bispecific antibodies represent novel and effective treatment options for patients with pretreated HER2-mutant and HER2-low metastatic breast cancer, but the successful integration of these regimens into care will require further investigation into current definitions of HER2 positivity.

July 16th 2022, 5:25pm

International Congress on the Future of Breast Cancer East

The emergence of novel agents like trastuzumab deruxtecan and tucatinib in the HER2-positive breast cancer treatment paradigm have served to markedly improve outcomes for those with this disease, according to Mark Pegram, MD, who added that the future looks bright.

July 15th 2022, 8:45pm

International Congress on the Future of Breast Cancer East

Charles M. Perou, PhD, discusses the role of intrinsic tumor subtyping in treatment decisions and outcomes for patients with breast cancer.

July 15th 2022, 6:00pm

International Congress on the Future of Breast Cancer East

Adrienne G. Waks, MD, highlights clinical trials that are studying emerging treatment escalation and de-escalation strategies in early stage HER2-positive breast cancer, elaborates on the future of immunotherapy in this setting, and explains the significance of establishing new biomarkers.

July 15th 2022, 5:30pm

International Congress on the Future of Breast Cancer East

Premenopausal patients with early hormone receptor–positive, HER2-negative breast cancer can benefit from chemotherapy, although it is still debatable whether that benefit stems from the chemotherapy itself or the ovarian function suppression that happens as a result of chemotherapy.

July 14th 2022, 10:00pm

Adrienne G. Waks, MD, discusses the continued evaluation of immunotherapy in HER2-positive breast cancer.

July 14th 2022, 9:54pm

Kevin Kalinsky, MD, MS, discusses the relationship between ovarian function suppression and chemotherapy benefits in premenopausal patients with HR–positive breast cancer.

July 2nd 2022, 2:21pm

ESMO Gastrointestinal Cancers Congress

Patients with previously treated metastatic HER2-positive colorectal cancer experienced clinically meaningful and durable responses to treatment with tucatinib plus trastuzumab, according to data from the phase 2 MOUNTAINEER trial.

June 30th 2022, 9:46pm

ESMO Gastrointestinal Cancers Congress

Harry H. Yoon, MD, discusses updated findings from the phase 3 RATIONALE-306 trial in esophageal squamous cell carcinoma.

June 30th 2022, 9:45pm

ESMO Gastrointestinal Cancers Congress

Arndt Vogel, MD, discusses the outcomes of the phase 3 HIMALAYA trial in unresectable hepatocellular carcinoma.

June 30th 2022, 8:00pm

ESMO Gastrointestinal Cancers Congress

A single priming dose of tremelimumab added to regular interval durvalumab generated significantly improved overall survival compared with sorafenib in the frontline setting for patients with unresectable hepatocellular carcinoma, irrespective of of their baseline albumin-bilirubin grade, according to updated data from the phase 3 HIMALAYA trial.

June 30th 2022, 7:05pm

ESMO Gastrointestinal Cancers Congress

Philip A. Philip, MD, PhD, FRCP, discusses unmet needs for patients with pancreatic cancer, emerging targets and agents in the space, and his hopes for future developments in the field.

June 30th 2022, 5:00pm

ESMO Gastrointestinal Cancers Congress

The combination of tislelizumab and chemotherapy demonstrated a superior overall survival benefit compared with chemotherapy alone in patients with metastatic or unresectable esophageal squamous cell carcinoma

June 30th 2022, 1:00pm

ESMO Gastrointestinal Cancers Congress

The addition of durvalumab to gemcitabine and cisplatin demonstrated an improvement in overall survival vs gemcitabine and cisplatin plus placebo as frontline therapy in patients with advanced biliary tract cancer, regardless of primary tumor location.

June 29th 2022, 10:34pm

ESMO Gastrointestinal Cancers Congress

The combination of botensilimab and balstilimab elicited deep objective responses with evidence of durability and encouraging tolerability in heavily pretreated patients with microsatellite stable, metastatic colorectal cancer.

June 29th 2022, 6:49pm

ESMO Gastrointestinal Cancers Congress

A second-line combination regimen comprised of RGX-202-01, FOLFIRI and bevacizumab demonstrated an encouraging efficacy signal and a favorable toxicity profile in patients with KRAS-mutant colorectal cancer.

June 15th 2022, 10:38pm

European Hematology Association Congress

The addition of venetoclax to ibrutinib resulted in a high rate of minimal residual disease negativity in the blood and marrow of patients with previously untreated chronic lymphocytic leukemia.

June 14th 2022, 8:58pm

Apalutamide plus androgen deprivation therapy and radiotherapy was evaluated in patients with high- and very high–risk localized or locally advanced prostate cancer, with RT schedules that are reflective of recommended practice guidelines.